Dai ichi Life Insurance Company Ltd Sells 105,043 Shares of Boston Scientific Corporation $BSX

Posted by Stanley Muller on Jul 25th, 2026

Boston Scientific logo Dai ichi Life Insurance Company Ltd decreased its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 31.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 231,497 shares of the medical equipment provider’s stock after selling 105,043 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Boston Scientific were worth $14,526,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in BSX. Norges Bank bought a new position in shares of Boston Scientific in the fourth quarter worth about $2,199,395,000. Assenagon Asset Management S.A. boosted its position in Boston Scientific by 133.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock valued at $631,135,000 after buying an additional 5,751,760 shares during the period. Maverick Capital Ltd. bought a new position in Boston Scientific in the 4th quarter worth about $280,735,000. Arrowstreet Capital Limited Partnership grew its stake in Boston Scientific by 25.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after acquiring an additional 2,856,040 shares in the last quarter. Finally, Farallon Capital Management LLC increased its position in shares of Boston Scientific by 56.7% during the fourth quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock worth $709,362,000 after acquiring an additional 2,693,007 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

BSX has been the subject of several research analyst reports. Truist Financial lowered their price target on Boston Scientific from $64.00 to $62.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Wells Fargo & Company restated an “equal weight” rating and set a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. Royal Bank Of Canada decreased their target price on Boston Scientific from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Needham & Company LLC cut their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $79.84.

Check Out Our Latest Research Report on BSX

Boston Scientific Price Performance

NYSE BSX opened at $44.26 on Friday. The company has a market cap of $65.78 billion, a PE ratio of 18.52, a P/E/G ratio of 0.84 and a beta of 0.58. The firm’s 50 day moving average price is $47.21 and its 200-day moving average price is $64.06. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.75 earnings per share. Sell-side analysts forecast that Boston Scientific Corporation will post 3.35 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.